BenevolentAI is a leading clinical-stage AI-enabled drug discovery and development company. Through their innovative AI technology, they empower scientists to uncover new insights from data, accelerating innovation and increasing the probability of discovering successful drugs. Their drug discovery platform and pipeline span from target identification to clinical trials, with a focus on improving the probability of clinical success.

BenevolentAI partners with renowned pharmaceutical and biotech companies to tackle therapeutic challenges and develop novel drugs for complex diseases. They are committed to environmental, social, and governance (ESG) stewardship, weaving sustainability into their mission. Investors can find comprehensive information about BenevolentAI's business, including reports, presentations, and governance, on their investor relations page.

In the news and media section, you can stay updated on their AI-driven drug and research programs, collaborations, investments, and events. If you are passionate about uniting AI and cutting-edge science, BenevolentAI offers exciting career opportunities to join their mission of discovering and developing new medicines for complex diseases